The lupus anticoagulant. A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA.

The lupus anticoagulant (LA) was demonstrated in 37% of 52 consecutive systemic lupus erythematosus (SLE) patients and patients with lupus-like syndromes, who were referred to our unit. The LA was found to be associated with a biologic false-positive VDRL (P less than 0.005), and the apparently paradoxical association of LA with vascular thromboses was confirmed (P less than 0.05). The presence of LA and a biologic false-positive VDRL defined a group of 7 antinuclear antibody negative patients with characteristic features of recurrent thromboses, spontaneous abortions, neurologic involvement, and renal disease. Further studies on 6 selected sera demonstrated LA in all 6 IgM fractions and in 3 of 6 IgG fractions. Inhibition of LA was shown in 6 of 9 Ig fractions after absorption with double-stranded DNA (dsDNA). Anticardiolipin antibody was shown by immunodiffusion in 3 LA positive IgG fractions from VDRL negative sera. Cardiolipin micelles partially inhibited anti-dsDNA binding of 4 IgG fractions, 3 of which were LA negative. In this report we discuss the overlapping specificities due to cross-reactivity between LA, anticardiolipin, and anti-dsDNA antibodies in human SLE, and we suggest that LA be considered equivalent to the biologic false-positive VDRL as a criterion for the diagnosis of SLE.

[1]  R. Schwartz,et al.  Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. , 1983, The New England journal of medicine.

[2]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[3]  G. Hughes,et al.  Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. , 1982, Annals of the rheumatic diseases.

[4]  T. Koike,et al.  Specificity of mouse hybridoma antibodies to DNA. , 1982, Immunology letters.

[5]  G. Hughes,et al.  Radioimmunoassay profile of antiglobulins in connective tissue diseases: elevated level of IgA antiglobulin in systemic sicca syndrome. , 1981, Clinical and experimental immunology.

[6]  R. Schwartz,et al.  Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids , 1981, The Journal of experimental medicine.

[7]  S. Shapiro,et al.  Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. , 1980, The Journal of clinical investigation.

[8]  N. Radford,et al.  POSSIBLE RELATIONSHIP BETWEEN LUPUS INHIBITOR AND RECURRENT ABORTION IN YOUNG WOMEN , 1980, The Lancet.

[9]  D. Gladman,et al.  Venous syndromes and pulmonary embolism in systemic lupus erythematosus. , 1980, Annals of the rheumatic diseases.

[10]  S. Rapaport,et al.  Thrombosis in patients with the lupus anticoagulant. , 1980, Annals of internal medicine.

[11]  P. Mannucci,et al.  The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant. , 2009, Scandinavian journal of haematology.

[12]  Y. Sultan,et al.  Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. , 1979, The Journal of laboratory and clinical medicine.

[13]  M. Reichlin,et al.  The clinical significance of autoantibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases. , 1979, The Journal of rheumatology.

[14]  E. Jaffe,et al.  A clinical study of the lupus anticoagulant. , 1976, Blood.

[15]  L. Horton,et al.  CHRONIC NON-SPECIFIC ENDOMETRITIS , 1976, The Lancet.

[16]  I. Nilsson,et al.  Intrauterine death and circulating anticoagulant ("antithromboplastin"). , 2009, Acta medica Scandinavica.

[17]  N. Talal,et al.  IgM and IgG antibodies to DNA, RNA, and DNA:RNA in systemic lupus erythematosus. , 1975, Clinical immunology and immunopathology.

[18]  H. Kronenberg,et al.  STUDIES ON PHOSPHOLIPIDS IN THE ACTION OF A LUPUS COAGULATION INHIBITOR , 1975, Pathology.

[19]  M. Guarnieri,et al.  A DNA antigen that reacts with antisera to cardiolipin. , 1974, Biochemical and biophysical research communications.

[20]  D. Doniach,et al.  A collagen disorder of the nervous system presenting as multiple sclerosis. , 1972, Brain : a journal of neurology.

[21]  G. L. Noel,et al.  Character of anti-DNA antibodies in systemic lupus erythematosus. , 1971, Clinical and experimental immunology.

[22]  D. Estes,et al.  THE NATURAL HISTORY OF SYSTEMIC LUPUS ERYTHEMATOSUS BY PROSPECTIVE ANALYSIS , 1971, Medicine.

[23]  Y. Et,et al.  Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. , 1965 .

[24]  S. Nojima,et al.  The specificity of cardiolipin in the serological reaction. , 1965, Journal of biochemistry.

[25]  E. Bowie,et al.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS. , 1963, The Journal of laboratory and clinical medicine.

[26]  D. Jackson,et al.  CIRCULATING ANTICOAGULANTS: A STUDY OF 40 CASES AND A REVIEW OF THE LITERATURE , 1961, Medicine.

[27]  A. Loeliger,et al.  Prothrombin as Co-Factor of the Circulating Anticoagulant in Systemic Lupus Erythematosus? , 1959, Thrombosis and Haemostasis.

[28]  I. Nilsson,et al.  Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases. , 1957, The Journal of laboratory and clinical medicine.

[29]  P. Frick,et al.  Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency. , 1955, Blood.